Skin and oral lesions associated to imatinib mesylate therapy

Support Care Cancer. 2009 Apr;17(4):465-8. doi: 10.1007/s00520-008-0536-8. Epub 2008 Nov 27.

Abstract

Introduction: Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects.

Results and discussion: Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph+ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Benzamides
  • Dose-Response Relationship, Drug
  • Drug Eruptions / etiology
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Male
  • Middle Aged
  • Oral Ulcer / chemically induced*
  • Oral Ulcer / pathology
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate